Skip to main content
CTOS 2024 Main banner
Final Program


Schedule at a Glance
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

(P 139) CHARACTERIZATION OF GLYCOSPHINGOLIPIDS IN HUMAN LEIOMYOSARCOMA

    Author(s)

  • Anders Thornell, MD, PhD (he/him/his)

    Senior Consultant
    University of Gothenburg, Institute of Clinical Scinces
    Gothenburg, Vastra Gotaland, Sweden

    • Co-Author(s)

  • CJ

    Chunsheng Jin, Ph.D.

    Researcher
    University of Gothenburg, Department of Medical Biochemistry and Cell Biology
    Gothenburg, Vastra Gotaland, Sweden

  • KS

    Karin Säljö, Associate Professor

    Senior Consultant
    University of Gothenburg, Institute of Clinical Scinces
    Gothenburg, Vastra Gotaland, Sweden

  • EJ

    Eva Jennische, Professor

    Researcher
    University of Gothenburg, Department of Medical Biochemistry and Cell Biology
    Gothenburg, Vastra Gotaland, Sweden

  • ST

    Susan Teneberg, Professor

    Researcher
    University of Gothenburg, Department of Medical Biochemistry and Cell Biology
    Gothenburg, Vastra Gotaland, Sweden

Objective: Leiomyosarcoma (LMS) is rare and malignant mesenchymal tumor often with poor prognosis. Thus, development of new tumor biomarkers for early detection of these cancers is urgently needed. Altered and aberrant glycosylation signatures is frequently found in cancers.
We herein have characterized the glycosphingolipids (GSL) by mass spectrometry, enzymatic hydrolysis and by binding of carbohydrate recognizing ligands.

Methods: The GSLs were characterized by mass spectrometry, enzymatic digestion, and by binding of a battery of carbohydrate recognizing ligands, and the tissue distribution of selected compounds was investigated by immunohistochemistry.

Results: The GSLs characterized in the LMS were globo- and lactotriaosylceramide, globotetraosylceramide, H type 2 penta- and heptaosylceramide, neolactotetra- and heptaosylceramide, and the gangliosides GM3, GD3, GM2, GD1a, sialylneolactotetra- and hexaosylceramide. The LMS had a complex GSL composition, and, in addition to the compounds listed above, we here provide the first evidence of the expression of sialyl-lactotetra, sialyl-globotetra, globopenta/SSEA-3, sialyl-globopenta/SSEA-4 and disialyl-globopenta.

Conclusion: Interestingly, in our previous study of GSLs in human pluripotent stem cell (hESC and hiPSC), all these glycosphingolipids were characterized. These insights may have important clinical implications for the development of novel diagnostic and therapeutic strategies for LMS.